Zentalis Pharmaceuticals 2023 Corporate Presentation

Zentalis Pharmaceuticals is a clinical-stage oncology company developing first-in-class therapeutics for difficult-to-treat cancers, with lead candidate azenosertib (ZN-c3), a WEE1 inhibitor showing best-in-class monotherapy activity and synergistic effects in combination settings. The company is pursuing a registrational path across ovarian cancer, uterine serous carcinoma, and additional indications with potential to address 140,000+ patients annually.